Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 3/20 | 0.36 |
| ▸ | ADH1C | P00326 | 2/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7201658 | 0.98 | ADH1A (0.39) | ADH1AADH1CADH1BDRD2DRD3 | |
| SCHEMBL13397455 | 0.91 | DRD2 (0.33) | DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL14355686 | 0.86 | ADH1A (0.37) | ADH1AADH1CADH1BDRD2DRD3 | |
| SCHEMBL14398636 | 0.80 | KMT2A (0.35) | ADH1AADH1CADH1B | |
| SCHEMBL17914491 | 0.80 | ADH1A (0.45) | ADH1AADH1CADH1BDRD2DRD3 | |
| SCHEMBL9927917 | 0.78 | ADH1A (0.41) | ADH1AADH1CADH1B | |
| SCHEMBL17914487 | 0.78 | ADH1A (0.47) | ADH1AADH1CADH1BDRD2DRD3 | |
| SCHEMBL104059 | 0.78 | ADH1A (0.36) | ADH1AADH1CADH1B | |
| SCHEMBL736236 | 0.78 | ADH1A (0.36) | ADH1AADH1CADH1B | |
| SCHEMBL13397397 | 0.78 | DRD2 (0.32) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024141757-A1 | LSD1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2024-07-04 | — | — | WO | disclosed |
| EP-1292604-B1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| EP-1292604-B1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7094769-B2 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060122145-A1 | 2-Aminocarbonyl-9H-purine derivatives | PFIZER INC | 2006-06-08 | — | — | US | disclosed |
| US-6921753-B2 | Purine derivatives | PFIZER INC (US) | 2005-07-26 | — | — | US | disclosed |
| US-6753322-B2 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC | 2004-06-22 | — | — | US | disclosed |
| EP-1296996-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2004-05-26 | — | — | EP | disclosed |
| US-20040077584-A1 | 2-Aminocarbonyl-9H-purine derivatives | PFIZER INC | 2004-04-22 | — | — | US | disclosed |
| US-6624158-B2 | Compound for use in the treatment of; sepsis, urogential, psychological, nervous system, respiratory, inflammatory, skin vascular and arthritic; wound healing agents | PFIZER INC | 2003-09-23 | — | — | US | disclosed |
| EP-1317465-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020072597-A1 | Purine derivatives | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-20020058641-A1 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2002022630-A1 | PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2002-03-21 | — | — | WO | disclosed |
| US-20020032168-A1 | Purine derivatives | PFIZER INC. | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122145-A1 | 2-Aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A2 | ADH1A 1523/4885ADH1C 2087/4885ADH1B 606/4885 |
| US-20040077584-A1 | 2-Aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A2 | ADH1A 1251/4885ADH1C 1755/4885ADH1B 576/4885 |
| US-20020032168-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | ADH1A 554/4885ADH1C 1326/4885ADH1B 993/4885 |
| US-20020058641-A1 | 2-aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A1 | ADH1A 832/4885ADH1C 1206/4885ADH1B 476/4885 |
| US-20020072597-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | ADH1A 554/4885ADH1C 1326/4885ADH1B 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.